Drug-drug interactions that interfere with statin metabolism

Expert Opinion on Drug Metabolism and Toxicology

Volumn 11, Issue 9, 2015, Pages 1435-1447

  Hirota, Takeshi ^a   Ieiri, Ichiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Atorvastatin; CYP2C9; CYP3A4; Electric medical record; Fluvastatin; Lovastatin; Simvastatin

Indexed keywords

CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

AREA UNDER THE CURVE; DRUG INTERACTION; DRUG METABOLISM; ELECTRONIC MEDICAL RECORD; FOOD DRUG INTERACTION; GENETIC POLYMORPHISM; HEREDITY; HUMAN; PHARMACODYNAMICS; REVIEW; ATHEROSCLEROSIS; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; METABOLISM; MUSCLE DISEASE; RHABDOMYOLYSIS;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CYTOCHROME P-450 ENZYME INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; POLYMORPHISM, GENETIC; RHABDOMYOLYSIS;

EID: 84939802008     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2015.1056149     Document Type: Review

References (141)

1. Rodwell VW, Nordstrom JL, Mitschelen JJ. Regulation of HMG-CoA reductase. Adv Lipid Res 1976;14:1-74
2. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343(6257):425-30
3. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 1976;72(2):323-6
4. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001;2(5):205-7
5. Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006;97(8A):61C-8C
6. Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004;13(7):417-26
7. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002;25(9):649-63
8. Hedenmalm K, Alvan G, Ohagen P, Dahl M-LL. Muscle toxicity with statins. Pharmacoepidemiol Drug Saf 2010;19(3):223-31
9. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988;62(15):28J-34J
10. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the scandinavian simvastatin survival study. Arch Int Med 1996;156(18):2085-92
11. Kasliwal R, Wilton LV, Cornelius V, et al. Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients. Drug Saf 2007;30(2):157-70
12. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005;19(6):403-14
13. Hrab RV, Hartman HA, Cox RH. Prevention of fluvastatin-induced toxicity, mortality, and cardiac myopathy in pregnant rats by mevalonic acid supplementation. Teratology 1994;50(1):19-26
14. Flint OP, Masters BA, Gregg RE, Durham SK. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol 1997;145(1):99-110
15. Gadbut AP, Caruso AP, Galper JB. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. J Molecul Cell Cardiol 1995;27(10):2397-402
16. Smith PF, Eydelloth RS, Grossman SJ, et al. HMG-CoA reductase inhibitorinduced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 1991;257(3):1225-35
17. Davidson MH, Stein EA, Dujovne CA, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997;79(1):38-42
18. Nakai A, Nishikata M, Uchida T, et al. Enhanced myopathy following administration of hypolipidemic agents under urethane anesthesia. Biol Pharmaceut Bull 1997;20(1):104-6
19. Molden E, Andersson KS, Jacobsen D. Interactions between statins and macrolide antibiotics. Tidsskr Nor Laegeforen 2007;127(12):1660-1
20. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006;114(25):2788-97
21. Nakai D, Nakagomi R, Furuta Y, et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 2001;297(3):861-7
22. Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006;97(8A):27C-31C
23. Egger SS, Rätz Bravo AE, Hess L, et al. Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging 2007;24(5):429-40
24. Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 2006;5(1):145-56
25. Heerey A, Barry M, Ryan M, Kelly A. The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 2000;169(3):176-9
26. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002;36(9):1331-6
27. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. Ann Rev Pharmacol Toxicol 1992;32:185-209
28. Schwartz JB. Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clin Pharmacol Ther 2009;85(2):198-203
29. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41(5):343-70
30. Garcá MJ, Reinoso RF, Sánchez Navarro A, Prous JR. Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 2003;25(6):457-81
31. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006;112(1):71-105
32. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 2008;47(7):463-74
33. Lennernäs H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003;42(13):1141-60
34. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001;57(5):357-64
35. Bhindi R, Ormerod O, Newton J, et al. Interaction between statins and clopidogrel: is there anything clinically relevant? QJM 2008;101(12):915-25
36. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80(6):565-81
37. Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet 2000;39(6):397-412
38. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002;42(9):963-70
39. Fujino H, Saito T, Tsunenari Y, Kojima J. Effect of gemfibrozil on the metabolism of pitavastatin-determining the best animal model for human CYP and UGT activities. Drug Metabol Drug Interact 2004;20(1-2):25-42
40. Puccetti L, Santilli F, Pasqui AL, et al. Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis 2011;214(1):122-8
41. Brown CM, Reisfeld B, Mayeno AN. Cytochromes P450: a structure-based summary of biotransformations using representative substrates. Drug Metabol Rev 2008;40(1):1-100
42. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/ genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008;392(6):1093-108
43. Park J-EE, Kim K-BB, Bae SK, et al. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica 2008;38(9):1240-51
44. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999;84(3):413-28
45. Bolego C, Baetta R, Bellosta S, et al. Safety considerations for statins. Cur Opin Lipidol 2002;13(6):637-44
46. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol 2004;93(1):104-7
47. Rebbeck TR, Jaffe JM, Walker AH, et al. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Nat Cancer Instit 1998;90(16):1225-9
48. Ball SE, Scatina J, Kao J, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4. Clin Pharmacol Ther 1999;66(3):288-94
49. Westlind A, Lofberg L, Tindberg N, et al. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. Biochem Biophys Res Commun 1999;259(1):201-5
50. Sata F, Sapone A, Elizondo G, et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000;67(1):48-56
51. Wandel C, Witte JS, Hall JM, et al. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4 1B5'-promoter region polymorphism. Clin Pharmacol Ther 2000;68(1):82-91
52. Eiselt R, Domanski TL, Zibat A, et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 2001;11(5):447-58
53. Moes DJ, Swen JJ, den Hartigh J, et al. Effect of CYP3A4∗22, CYP3A5 3, and CYP3A combined genotypes on cyclosporine, everolimus, and tacrolimus pharmacokinetics in renal transplantation. CPT 2014;3:e100
54. Hirota T, Takane H, Higuchi S, Ieiri I. Epigenetic regulation of genes encoding drug-metabolizing enzymes and transporters; DNA methylation and other mechanisms. Cur Drug Metabol 2008;9(1):34-8
55. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Gen 2001;27(4):383-91
56. Kivisto KT, Niemi M, Schaeffeler E, et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 2004;14(8):523-5
57. Fiegenbaum M, da Silveira FR, Van der Sand CR, et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 2005;78(5):551-8
58. Guo Y, Wang Y, Si D, et al. Catalytic activities of human cytochrome P450 2C9 1, 2C9 3 and 2C9 13. Xenobiotica 2005;35(9):853-61
59. Kirchheiner J, Kudlicz D, Meisel C, et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterollowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther 2003;74(2):186-94
60. Buzková H, Pechandová K, Danzig V, et al. Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population. Med Sci Monit 2012;18(8):CR512-17
61. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326(7404):1423
62. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97(8A):52C-60C
63. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998;46(1):49-53
64. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60(1):54-61
65. Ishigam M, Uchiyama M, Kondo T, et al. Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions. Pharmaceut Res 2001;18(5):622-31
66. Molden E, Andersson KS. Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients. Pharmacotherapy 2007;27(4):603-7
67. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004;94(9):1140-6
68. Penzak SR, Chuck SK, Stajich GV. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy 2000;20(9):1066-71
69. Schmassmann-Suhijar D, Bullingham R, Gasser R, et al. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 1998;351(9120):1929-30
70. Pichard L, Domergue J, Fourtanier G, et al. Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450. Biochem Pharmacol 1996;51(5):591-8
71. Regazzi MB, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993;25(4):2732-4
72. Hedman M, Neuvonen PJ, Neuvonen M, et al. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther 2004;75(1):101-9
73. Asberg A. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs 2003;63(4):367-78
74. Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004;76(2):167-77
75. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006;34(7):1229-36
76. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002;72(6):685-91
77. Mück W, Ochmann K, Rohde G, et al. Influence of erythromycin pre-and cotreatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol 1998;53(6):469-73
78. Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 2003;33(Suppl 2):23-30
79. Kantola T, Backman JT, Niemi M, et al. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000;56(3):225-9
80. Mogyorósi A, Bradley B, Showalter A, Schubert ML. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin. J Int Med 1999;246(6):599-602
81. Igel M, Sudhop T, von Bergmann K. Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol 2002;42(8):835-45
82. Schmitz G, Schmitz-Madry A, Ugocsai P. Pharmacogenetics and pharmacogenomics of cholesterollowering therapy. Cur Opin Lipidol 2007;18(2):164-73
83. Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metabol Dispos 2002;30(11):1280-7
84. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on cerivastatin pharmacokinetics. Eur J Clin Pharmacol 1999;54(11):851-5
85. Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/ OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004;311(1):228-36
86. Ishikawa C, Ozaki H, Nakajima T, et al. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. J Human Gen 2004;49(10):582-5
87. Goosen TC, Bauman JN, Davis JA, et al. Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos 2007;35(8):1315-24
88. Prueksaritanont T, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997;25(10):1191-9
89. Backman JT, Kyrklund C, Kivisto KT, et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000;68(2):122-9
90. Kyrklund C, Backman JT, Kivisto KT, et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001;69(5):340-5
91. Shitara Y, Itoh T, Sato H, et al. Inhibition of transporter-mediated hepatic uptake as a mechanism for drugdrug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 2003;304(2):610-16
92. Karlgren M, Ahlin G, Bergstrom CA, et al. In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Pharmaceut Res 2012;29(2):411-26
93. Polgar O, Robey RW, Bates SE. ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol 2008;4(1):1-15
94. Takeuchi K, Sugiura T, Matsubara K, et al. Interaction of novel plateletincreasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans. Drug Metab Dispos 2014;42(4):726-34
95. Dobrinska MR, Stubbs RJ, Gregg MH. Effects of dose and food on HMG-CoA reductase inhibitor profiles after lovastatin (mevacor). Pharm Res 1988;5:S182
96. Pan HY, DeVault AR, Brescia D, et al. Effect of food on pravastatin pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol 1993;31(6):291-4
97. Radulovic LL, Cilla DD, Posvar EL, et al. Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol 1995;35(10):990-4
98. Whitfield LR, Stern RH, Sedman AJ, et al. Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMGCoA reductase. Eur J Drug Metabol Pharmacokinet 2000;25(2):97-101
99. Dujovne CA, Davidson MH. Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy. Am J Med 1994;96(6A):37S-40S
100. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998;46(2):101-10
101. Bailey DG, Spence JD, Munoz C, Arnold JM. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991;337(8736):268-9
102. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMGCoA reductase inhibitors. Clin Pharmacol Ther 1998;64(5):477-83
103. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998;63(4):397-402
104. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 1999;66(2):118-27
105. Ando H, Tsuruoka S, Yanagihara H, et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol 2005;60(5):494-7
106. Reddy P, Ellington D, Zhu Y, et al. Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. Br J Clin Pharmacol 2011;72(3):434-41
107. Hu M, Mak VW, Yin OQ, et al. Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of pitavastatin. Drug Metab Pharmacokinet 2013;28(2):104-8
108. Jacobsen W, Kirchner G, Hallensleben K, et al. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 1999;27(2):173-9
109. Lilja JJ, Kivisto KT, Neuvonen PJ. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther 2000;68(4):384-90
110. Thummel KE, Brimer C, Yasuda K, et al. Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol Pharmacol 2001;60(6):1399-406
111. Thompson PD, Jurutka PW, Whitfield GK, et al. Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. Biochem Biophys Res Commun 2002;299(5):730-8
112. Drocourt L, Ourlin J, Pascussi J, et al. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem 2002;277(28):25125-32
113. Ucar M, Neuvonen M, Luurila H, et al. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol 2004;59(12):879-82
114. Kyrklund C, Backman JT, Kivisto KT, et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000;68(6):592-7
115. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2004;57(2):181-7
116. Faltaos DW, Urien S, Carreau V, et al. Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. Fundam Clin Pharmacol 2006;20(3):321-30
117. Kakara M, Nomura H, Fukae M, et al. Population pharmacodynamic analysis of LDL-cholesterol lowering effects by statins and co-medications based on electronic medical records. Br J Clin Pharmacol 2014;78(4):824-35
118. Hayashi T, Yokote K, Saito Y, Iguchi A. Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opin Pharmacot 2007;8(14):2315-27
119. Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract 2005;59(2):239-52
120. Elsby R, Hilgendorf C, Fenner K. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1. Clin Pharmacol Ther 2012;92(5):584-98
121. Parke-Davis-Pfizer. Lipitor (atorvastatin calcium) tablets for oral administration prescribing information. Available from: http://labeling. pfizer. com/ShowLabeling. aspx?id=587 [Last accessed 19 November 2014]
122. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr 2005;39(3):307-12
123. Kovarik JM, Hartmann S, Hubert M, et al. Pharmacokinetic and pharmacodynamic assessments of HMGCoA reductase inhibitors when coadministered with everolimus. J Clin Pharmacol 2002;42(2):222-8
124. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 2005;78(2):154-67
125. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998;64(1):58-65
126. Mazzu AL, Lasseter KC, Shamblen EC, et al. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000;68(4):391-400
127. Bullman J, Nicholls A, Van Landingham K, et al. Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers. Epilepsia 2011;52(7):1351-8
128. Teng R, Mitchell PD, Butler KA. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol 2013;69(3):477-87
129. Azie NE, Brater DC, Becker PA, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998;64(4):369-77
130. Merck & Co. Inc. MEVACOR (lovastatin) tablets. Available from: http://www. merck. com/product/usa/pi circulars/m/mevacor/mevacor-pi. pdf [Last accessed 19 November 2014]
131. Hoch M, Hoever P, Alessi F, et al. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects. Eur J Clin Pharmacol 2013;69(3):523-32
132. Merck & Co. Inc. ZOCOR (simvastatin) tablets prescribing information. Available from: http://www. merck. com/product/ usa/pi-circulars/z/zocor/zocor-pi. pdf [Last accessed 19 November 2014]
133. Simard C, O'Hara GE, Prévost J, et al. Study of the drug-drug interaction between simvastatin and cisapride in man. Eur J Clin Pharmacol 2001;57(3):229-34
134. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998;64(2):177-82
135. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63(3):332-41
136. Gehin M, Sidharta PN, Gnerre C, et al. Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist. Eur J Clin Pharmacol 2014; In press
137. Novartis Pharmaceuticals Corporation. Lescol (fluvastatin sodium) cap-sules/ Lescol XL (fluvastatin sodium) extendedrelease tablets for oral use prescribing information. Available from: https:// www. pharma. us. novartis. com/product/pi/ pdf/Lescol. pdf [Last accessed 19 November 2014]
138. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994;73(14):3D-11D
139. Ayalasomayajula SP, Vaidyanathan S, Kemp C, et al. Effect of clopidogrel on the steady-state pharmacokinetics of fluvastatin. J Clin Pharmacol 2007;47(5):613-19
140. Spence JD, Munoz CE, Hendricks L, et al. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995;76(2):80A-3A
141. Smith HT, Jokubaitis LA, Troendle AJ, et al. Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens 1993;6(11 Pt 2):375S-82S